无菌性
aseptically filled
浓度
6% in 0.9% NaCl
SMILES字符串
OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O.OCCOC[C@H]2O[C@H](OCCO)[C@H](OCCO)[C@@H](OCCO)[C@@H]2OCCO
法规信息
新产品
Ryan Zarychanski et al.
JAMA, 309(7), 678-688 (2013-02-21)
Hydroxyethyl starch is commonly used for volume resuscitation yet has been associated with serious adverse events, including acute kidney injury and death. Clinical trials of hydroxyethyl starch are conflicting. Moreover, multiple trials from one investigator have been retracted because of
Nicolai Haase et al.
BMJ (Clinical research ed.), 346, f839-f839 (2013-02-19)
To assess the effects of fluid therapy with hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin on mortality, kidney injury, bleeding, and serious adverse events in patients with sepsis. Systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
Ole Broch et al.
PloS one, 8(2), e56267-e56267 (2013-02-19)
The ability of stroke volume variation (SVV), pulse pressure variation (PPV) and global end-diastolic volume (GEDV) for prediction of fluid responsiveness in presence of pleural effusion is unknown. The aim of the present study was to challenge the ability of
Hydroxyethyl starch for intravenous volume replacement: more harm than benefit.
Massimo Antonelli et al.
JAMA, 309(7), 723-724 (2013-02-21)
Meta-analyses of hydroxyethyl starch for volume resuscitation.
John P A Ioannidis
JAMA, 309(21), 2209-2209 (2013-06-06)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门